SCHEMBL24046641

SCHEMBL24046641

Cc1ccc(NCCC(C)(C)c2cccc(N)c2)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.43
▸ MAPT P10636 6/20 0.43
▸ CYP3A4 P08684 1/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ TP53 P04637 1/20 0.40
▸ CCR2 P41597 1/20 0.40
▸ CCR5 P51681 1/20 0.40
▸ AGTR1 P30556 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ ICMT O60725 2/20 0.39
▸ TSHR P16473 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ DRD2 P14416 1/20 0.35
▸ DRD4 P21917 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ DHFR P00374 1/20 0.35
▸ RAPGEF4 Q8WZA2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30219722 1.00 ALDH1A1 (0.43) ALDH1A1MAPTCYP3A4SMN1; SMN2TP53
SCHEMBL30219774 0.85 TSHR (0.41) ALDH1A1MAPTTSHRMAPK1
SCHEMBL24046642 0.85 TSHR (0.41) ALDH1A1MAPTTSHRMAPK1
SCHEMBL30219731 0.77 ALDH1A1 (0.44) ALDH1A1MAPTSMN1; SMN2AGTR1GAA
SCHEMBL30219732 0.77 ALDH1A1 (0.44) ALDH1A1MAPTSMN1; SMN2AGTR1GAA
SCHEMBL30219764 0.72 CYP3A4 (0.41) MAPTCYP3A4SMN1; SMN2TP53CCR2
SCHEMBL24046542 0.72 CYP3A4 (0.41) MAPTCYP3A4SMN1; SMN2TP53CCR2
SCHEMBL24046535 0.72 CYP3A4 (0.44) ALDH1A1MAPTCYP3A4SMN1; SMN2AGTR1
SCHEMBL30219763 0.72 CYP3A4 (0.44) ALDH1A1MAPTCYP3A4SMN1; SMN2AGTR1
SCHEMBL25695740 0.70 CYP3A4 (0.41) MAPTCYP3A4SMN1; SMN2TP53CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192644-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
US-20230192644-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
WO-2021236885-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192644-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE IKZF2, IKZF1, NUTF2 ALDH1A1 1391/4885MAPT 950/4885CYP3A4 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback